ICML 2017 | The current status of CLL treatment

Ulrich Jäger

Ulrich Jäger, MD from the Medical University of Vienna, Vienna, Austria gives an overview on the novel treatments in relapsed/refractory chronic lymphocytic leukemia (CLL) session at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. Dr Jager explains how current treatments are changing rapidly and discusses 3 new drugs that have been introduced – BCL inhibitor venetoclax, PTK inhibitor ibrutinib and PI3 kinase inhibitor idelalisib. He also touches on minimal residual disease testing, the use of CAR T-cells and the million dollar question – will we be able to cure CLL?

Share this video